Top Tweets for #PeriniPicks
Getting ready to fire up the #ASH25 #ASH2025 #LeonardList daily countdown of top 10 #lymphoma abstracts over next 10 days - my annual thoughts on studies of interest and new data of importance to patients, clinicians and researchers @Perlmutter_CC @nyulangone
#PeriniPicks No. 2 - Rapid Ramp Up for Bispecifics.
We've all been there... Pts rapidly progressing, and BsAs needs ramp up that can take up to 3 weeks.
But rapid Ramp Up looks safe. And could be a new SoC if proved safe in larger cohorts.
https://t.co/ep6BWOB9CN
#PeriniPicks No. 3
New agents that caught my attention...
1. Zilovertamab Vedotin looks active in DLBCL and is moving now to first line therapy.
https://t.co/GjSNHnKDJz
#PeriniPicks No. 4 for #EHA2025:
De-escalation is a reality in PET-4 low risk DLBCL.
Updated results from the ph III trial of 4 R-CHOP + 2R x 6 R-CHOP in China or analysis of Optimal>60 shows that...
https://t.co/8tn6Aibglt
Ok, I usually dont do it, but I will make a short #PeriniPicks for #EHA2025. The list will have 5 abstracts/areas of interest.
If you don't agree, I will gladly discuss the list with you having a Negroni at the Duomo. Feel Free to invite me.
And no. 1 #PeriniPicks for #ASH24 could not be other:
https://t.co/57gexvg3Yw
"... ibrutinib+R-CHOP/R-DHAP induction followed by 2 years of ibrutinib maintenance should be the new standard of care in younger MCL patients, thus ending the era of ASCT for MCL patients"
#PeriniPicks No. 2 for #ASH24!
Is the era of chemotherapy over for MCL? The Enrich trial suggests so, especially if you use R-CHOP for elderly pts.
https://t.co/WBC5EgEO2r
Great trial showing that chemo-free regimens in MCL are a reality in a randomized trial.
#PeriniPicks No. 4 - Delayed immune events in patients treated with CPI + AVD
https://t.co/SokCnX6d3b
The future of HL therapy will be based on CPI, and with an increase in patients, more late events will be seen. Understand these events is essential.
#PeriniPicks No. 5 - First hit on ASCT in MCL
https://t.co/3puZSiKuPN
@timfenske and ECOG-ACRIN EA4151 investigators show that, for patients achieving MRD negativity after modern induction in MCL does not benefit from ASCT.
MRD was done by ClonoSeq, not avaliable in Latam.
#PeriniPicks No. 6 - SIXTEEN years follow up of the RAPID trial!
Great follow up showing amazing 15y-OS of 92.3% in PET Neg no IFRT patients. Most OS events were actually not HL.
For PET-2 positive (n=145), HL was the most common cause of death (7/20).
#PeriniPicks no.7 - Not all POD24 FL are the same
@DrCarlaCasulo et al shows that POD24 with transformation is a different kind of animal, and probably, but not alone, explains how bad these patients do.
https://t.co/XywkJ8fIj1
#PeriniPicks No.8 - How well do BsAs work for rare agressive lymphomas?
https://t.co/NfO3jieTbU
Quite well, actually, including PMBL, DHL, HBGL, NOS and BL.
Very interesting and good to know these histologies are not being forgotten.
We dont have CART easily avaliable...
#PeriniPicks No. 9:
Does COO by Hans is enough to select patients for Pola-based regimens?
Not in first line therapy!
Great work with >700 pts by @Eddie_Cliff et al.
Hans is the only avaliable tool for stratitification in our reality, so this is very needed info!
And #PeriniPicks No.10 starts with the 5y update of Polarix: https://t.co/jaOTzTxRSk
The so expected OS benefit... didnt come. 5y OS 82.2 x 79.6. There was PFS and DFS benefit, and follow up will follow since they observed deaths beyond 2y.
Alright Alright Alright!
Time for #PeriniPicks 2024. Again, I select abstracts relevant to LIC/LMIC, so no new fancy and $$ therapies.
This year, a big challenge to review 1697 lymphoma abstracts with no pictures or tables! Shame on you, @ASH_hematology! Lets fix it for 2025!
Learning with @JohnPLeonardMD, a great inspiration not only on Twitter (#PeriniPicks is clearly inspired by #LeonardList) but also as a very caring physician and amazing researcher.
Plus there is beer in this amazing @CCO_LLC.
And now, No.1 #PeriniPicks for #ASH23
Again, my colleagues of India showing it is possible to impact the whole world with research done in LMIC countries!
https://t.co/NODdtguR5w
Actaly-cell data will be presented, showing good results and a cost of $15,000.
#PeriniPicks No.2 for #ASH23.
New SoC for Elderly HL patients: Nivo-AVD.
There is no room for discussion after this great analysis of the S1826 led by @DrAEvens
HR=0.35, my friends. Cheaper, more tolerable and more efficient.
https://t.co/5qhhBhRLai
And now... Time for my Top 3 #PeriniPicks for #ASH23.
No. 3 has already been highly celebrated in twitter!
Modified EA consolidation in PCNSL by our Indian Colleagues has demonstrated better safety and efficacy. Great work by @bagalbp
https://t.co/dWRx7gYXRO
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers